新诺威公告公司已于2025年12月10日向香港联交所递交了发行境外上市股份（H股）并在香港联交所主 板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 ...

智通财经APP讯，新诺威(300765.SZ)发布公告，公司已于2025年12月10日向香港联交所递交了发行境外 上市股份(H股)并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市 的申请资料。本次发行上市事项的相关申请资料为公司按照香港证监会及香港联交所的要求编制和刊 发，为草拟版本，其所载资料可能会适时作出更新及修订。 ...

https://www1.hkexnews.hk/app/sehk/2025/107949/documents/sehk25121001233.pdf 中文： 关于向香港联交所递交境外上市股份（H 股）发行上市申请 并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）已于 2025 年 12 月 10 日向 香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境外上市股份（H 股）并在香港联交所主板挂牌上市（以下简称"本次发行上市"）的申请，并于同 日在香港联交所网站刊登了本次发行上市的申请资料。本次发行上市事项的相关 申请资料为公司按照香港证券及期货事务监察委员会（以下简称"香港证监会"） 及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新 及修订。 https://www1.hkexnews.hk/app/sehk/2025/107949/documents/sehk25121001232_c.pdf 鉴于本次发行上市的认购对象仅限于符合相关条件的境外投资者及依据中 国 ...

Company Overview - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (石药创新), has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [4] Business Development - In 2024, the company acquired control of Giant Bio, expanding its main business into the biopharmaceutical sector, marking a key step in its strategic transformation [5] - The company is developing innovative therapies targeting unmet clinical needs in significant disease areas such as tumors, autoimmune diseases, and infectious diseases [5] - The company has a strong pipeline with 15 drugs in clinical or late-stage development, including 9 ADC drugs and 1 mRNA vaccine [5] Financial Performance - The company's revenue for the fiscal years 2022, 2023, 2024, and the seven months ending July 31, 2025, were approximately RMB 2.838 billion, RMB 2.539 billion, RMB 1.980 billion, and RMB 1.241 billion respectively [9] - The company's profit for the same periods was approximately RMB 294 million, RMB 126 million, a loss of RMB 304 million, and a loss of RMB 226 million respectively [10] - The gross profit margin for the fiscal years 2022, 2023, 2024, and the seven months ending July 31, 2025, were approximately 46.8%, 45.6%, 41.8%, and 38.3% respectively [11] Industry Outlook - The global pharmaceutical market is expected to grow from USD 1,324.5 billion in 2019 to USD 1,542 billion in 2024, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030 [13] - The global oncology drug market is projected to grow from USD 143.5 billion in 2019 to USD 253.3 billion in 2024, with a CAGR of 12.0% [14] - The global antibody drug market is expected to expand from USD 163.8 billion in 2019 to USD 254.3 billion in 2024, with a CAGR of 9.2% [15]

Company Overview - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (stock code: 300765.SZ), has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [4] Business Development - In 2024, the company acquired control of Giant Bio, expanding its main business into the biopharmaceutical sector, marking a key step in its strategic transformation [5] - The company is engaged in the development of innovative therapies targeting unmet clinical needs in significant disease areas such as tumors, autoimmune diseases, and infectious diseases [5] - The company has a strong technical foundation in antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with plans to commercialize two antibody drugs in the second half of 2024 [5] Product Pipeline - As of December 1, 2025, the company has 15 drugs in clinical or late-stage development, including 9 ADCs and 1 mRNA vaccine [5] - The company’s mRNA vaccine products, including the first domestically developed COVID-19 mRNA vaccine, have been included for emergency use in China [5] Financial Performance - The company's revenue for the fiscal years ending July 31 for 2022, 2023, 2024, and the first seven months of 2025 were approximately RMB 2.838 billion, RMB 2.539 billion, RMB 1.980 billion, and RMB 1.241 billion respectively [8] - The company's profit for the same periods was approximately RMB 294 million, RMB 126 million, a loss of RMB 304 million, and a loss of RMB 226 million respectively [8] - The gross profit margin for these years was approximately 46.8%, 45.6%, 41.8%, and 38.3% [9] Industry Outlook - The global pharmaceutical market is expected to grow from USD 1,324.5 billion in 2019 to USD 1,542 billion in 2024, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030 [11] - The Chinese pharmaceutical market is projected to grow from RMB 1,629.7 billion in 2024 to RMB 2,129.7 billion in 2030, with a CAGR of 4.6% from 2024 to 2030 [11] - The global oncology drug market is expected to expand from USD 143.5 billion in 2019 to USD 253.3 billion in 2024, with a CAGR of 12.0% [12] Market Position - The company is positioned as a significant player in the biopharmaceutical sector, focusing on innovative therapies and addressing unmet clinical needs [5][11] - The company has established a solid partnership with leading beverage companies, leveraging its expertise in caffeine production and health food products [6]

Core Viewpoint - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (stock code: 300765.SZ), has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor. The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1]. Group 1: Company Overview - Shiyao Innovation has maintained its position as the world's largest producer of synthetic caffeine by revenue and shipment volume from 2020 to 2024, according to Frost & Sullivan [1]. - Since its establishment in 2006, the company has concentrated on the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [1]. Group 2: Market Presence - As of the latest feasible date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [1]. - The company has established solid partnerships with leading international beverage industry clients, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [1].

Group 1 - The company, Shiyao Innovation Pharmaceutical Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1] - According to Frost & Sullivan, the company has maintained its position as the world's largest producer of synthetic caffeine by revenue and volume from 2020 to 2024 [1][5] Group 2 - Since its establishment in 2006, the company has specialized in the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [5] - As of the last practicable date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [5] - The company has established solid partnerships with leading international beverage companies, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [5]

据港交所12月10日披露，石药创新制药股份有限公司(简称：石药创新，300765.SZ)向港交所主板递交 上市申请，中信证券为其独家保荐人。据招股书，该公司专注于生物制药、功能性原料及保健食品的研 发、生产与商业化。根据弗若斯特沙利文的资料，自2020年至2024年，按收入和出货量计，该公司始终 保持着全球最大化学合成咖啡因生产商地位。 | [編纂]項下的[編纂]數目 | : [编纂]股H股(視乎[編纂]) | | --- | --- | | [編纂]數目 | :「編纂]股H股(可予[編纂]) | | [編纂]數目 | : [編纂]股H股(可予[編纂]及[編纂]) | | 最高[編纂] | : 每股H股[編纂]港元,另加[編纂] | | | (「編纂]港元,多繳款項可予退還) | | 面值 | 每股H股人民幣1.00元 | | [編纂] | : [編纂] | 自2006年成立以来，该公司始终专注于高质量咖啡因的研发与生产。该公司主要生产用作功能性饮料中 的食品添加剂的咖啡因。根据弗若斯特沙利文的资料，自2020年至2024年，按收入和出货量计，该公司 始终保持着全球最大化学合成咖啡因生产商地位。截至最后实际可 ...

Group 1 - The company, Shiyao Innovation Pharmaceutical Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1] - According to Frost & Sullivan, the company has maintained its position as the world's largest producer of synthetic caffeine by revenue and volume from 2020 to 2024 [1][5] Group 2 - Since its establishment in 2006, the company has specialized in the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [5] - As of the last feasible date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [5] - The company has established solid partnerships with leading international beverage companies, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [5]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 本文件為草擬本，其所載資訊不完整及可作更改。閱讀本文件有關資料時，必須一併細閱本文件首頁「警告」一節。 CSPC Innovation Pharmaceutical Co., Ltd. 石藥創新製藥股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。閣下閱覽本文件，即代表 閣下知 悉、接納並向本公司、其獨家保薦人、保薦人兼整體協調人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據送呈香港公司註冊處處長登記的本 公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提 ...